LNTH vs TAK
Lantheus Holdings vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
LNTH
Lantheus Holdings
67
Buy
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | LNTH | TAK |
|---|
| AI Score |
67
|
67
|
| Price |
$100.63
|
$17.49
|
| P/E Ratio |
23.91×
|
48.87×
|
| ROE |
21.4%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
60.1%
|
62.1%
|
| Debt / Equity |
0.44×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
42.5
|
61.6
|
| Beta |
-0.057
|
0.088
|
| Expected Upside |
+7.8%
|
—
|
AI Committee View
Current Innellis committee reasoning for LNTH versus TAK.
The committee scores are tied.
LNTH and TAK both score 67/100.
LNTH Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical